Spots Global Cancer Trial Database for Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCC
Official Title: Anlotinib Hydrochloride In Combination With Radiofrequency Ablation And Transcatheter Arterial Chemoembolization in Patients With Middle-advanced Hepatocellular Carcinoma, Open, Single Arm, Exploratory Clinical Trial
Study ID: NCT04157140
Conditions
Study Description
Brief Summary: A single-arm, open-label clinical trial, focus on the safety and efficacy of anlotinib hydrochloride in combination with radiofrequency ablation (RFA) and transcatheter arterial chemoembolization(TACE) in patients with middle-advanced hepatocellular carcinoma(HCC)
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Beijing Ditan Hospital, Capital Medical University, Beijing, Beijing, China
The First Affiliated Hospital of Dalian Medical University, Dalian, , China
Shengjing Hospital Of China Medical University, Shenyang, , China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
